Retrospective evaluation of the predictive value of tumour burden at baseline [⁶⁸ Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT.

ABSTRACT:

Purpose

There is a lack of validated imaging biomarkers for prediction of response to peptide receptor radionuclide therapy (PRRT). The primary objective was to evaluate if tumour burden at baseline PET/CT could predict treatment outcomes to PRRT with [¹⁷⁷Lu]Lu-DOTA-TATE. Secondary objectives were to evaluate if there was a correlation between tumour burden and mean tumour absorbed dose (AD) during first cycle, and if mean tumour AD or the relative change of tumour burden at first follow-up PET/CT could predict progression free survival (PFS) or overall survival (OS).

Methods

Patients with gastroenteropancreatic neuroendocrine tumour (GEP-NET) treated with [¹⁷⁷Lu]Lu-DOTA-TATE PRRT were retrospectively included. Tumour burden was quantified from [⁶⁸

SUBMITTER: Galne A 

PROVIDER: S-EPMC11306659 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature